IVG
29.1.2020 10:02:13 CET | Business Wire | Press release
Two massive wins for IVG (I Vape Great) is the reason for their celebration. Over the last 4 years, IVG has sold 14 million bottles of e-liquid, the global e-liquid firm based in Preston has been selected to sell their products in 41 airport terminals and in 22 airports across the UK. After going head to head with some of the biggest names in the vape industry IVG has also been crowned UK’s Best Brand of 2019 at the Ecigclick Awards , which saw a record amount of voters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200129005020/en/
“We are delighted to have won this award and to have our products entering airports across the United Kingdom. We think this is a fantastic opportunity, not only for vapers but also for smokers wanting to switch to vaping worldwide ” – Ahsan Bawa CEO of IVG Premium E-Liquids.
Which IVG Products Will Be Available in The Airports?
By the end of January, we can expect to see a new easy to carry around travel pack with four of IVG’s world-renowned flavours and one new flavour exclusively available in airports, Bubblegum, Summer Blaze, Blue Raspberry, Silver Tobacco, and Super Ice Menthol. All the e-liquids will be available in 50PG/50VG 6mg and 12mg.
How Does This Benefit FMCG & Retail Sectors?
Opportunity - Vaping is tipped to be a £2.5bn market by 2025, with 80% of vapers looking to quit smoking. Threat - without an alternative, in 10 years, convenience retailers will have lost £107m every month.
IVG entering airports will raise awareness of Vaping, the opportunity for retailers to stock vaping products or improve on their selection of existing products and having a strong vaping brand as IVG will improve the chances of surviving the loss of sales from people switching to vaping from smoking.
What Does This Mean for The Vape Industry?
IVG is paving the way for vape brands being readily available in the FMCG & Retail sectors and as one of the worlds most recognised brands, IVG predicts that this will be a huge success which the whole vape industry can benefit from.
Airports Where You Can Find IVG E-Liquids
London Gatwick, London Heathrow, London Stanstead, Manchester, Bournemouth, Exeter, Eurotunnel, Jersey, Belfast, Prestwick, Glasgow, Aberdeen, Edinburgh, Newcastle, Birmingham, East Midlands, Bristol, Southampton, Liverpool, Leeds, Humberside and Doncaster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005020/en/
Social Media:
https://www.facebook.com/ivgeliquids
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom